Cellectis S.A.
cema-cel
first-line consolidation for large B-cell lymphoma (LBCL)
Countdown
358days
Advisory committee · ~ Jun 30, 2027 estimated
What's at stake
An FDA advisory committee reviews cema-cel for first-line consolidation for large B-cell lymphoma (LBCL) around ~ Jun 30, 2027. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 11h ago
“Allogene announced that study accrual is anticipated to be complete by the end of 2027 and that it anticipates an interim Event-Free Survival (EFS) analysis in mid-2027 and the primary EFS analysis in mid-2028.”